Live Webinar

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|February 2, 2012

Dr. Niteesh Choudhry Discusses Value-Based Insurance Design [Part 2 of 4]

Dr. Niteesh Choudhry, Associate Professor, Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics in Boston, shares that even when cost was taken out of the picture, more than half of the post-myocardial infarction patients in the study didn’t take their medications.

Dr. Choudhry notes that even though the intervention was designed to be simple, this population of cardiac patients displayed medication adherence issues beyond cost, such as forgetfulness, worry about side effects, and difficulty accessing the medications.

Related to this article

View more
Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Read more
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel. | Image: LinkedIn
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Read more